It is well established that mutant forms of the p53 tumour suppressor acquire pro-oncogenic activities. Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer
Breast Cancer Research Open Access 11 December 2018
-
Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer
Scientific Reports Open Access 14 July 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vousden, K. H. & Prives, C. Cell 137, 413–431 (2009).
Brosh, R. & Rotter, V. Nat. Rev. Cancer 9, 701–713 (2009).
Freed-Pastor, W. A. & Prives, C. Genes Dev. 26, 1268–1286 (2012).
Alexandrova, E. M. et al. Nature 523, 352–356 (2015).
Terzian, T. et al. Genes Dev. 22, 1337–1344 (2008).
Parrales, A. et al. Nat. Cell Biol. 18, 1233–1243 (2016).
Mullen, P. J., Yu, R., Longo, J., Archer, M. C. & Penn, L. Z. Nat. Rev. Cancer http://doi.org/brjq (2016).
Wiech, M. et al. PloS ONE 7, e51426 (2012).
Lukashchuk, N. & Vousden, K. H. Mol. Cell. Biol. 27, 8284–8295 (2007).
Krönke, J. et al. Science 343, 301–305 (2014).
Chauhan, D., Hideshima, T., Mitsiades, C., Richardson, P. & Anderson, K. C. Mol. Cancer Ther. 4, 686–692 (2005).
Walerych, D. et al. Nat. Cell Biol. 18, 897–909 (2016).
Xu, J. et al. Nat. Chem. Biol. 7, 285–295 (2011).
Freed-Pastor, W. A. et al. Cell 148, 244–258 (2012).
Sorrentino, G. et al. Nat. Cell Biol. 16, 357–366 (2014).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Freed-Pastor, W., Prives, C. Targeting mutant p53 through the mevalonate pathway. Nat Cell Biol 18, 1122–1124 (2016). https://doi.org/10.1038/ncb3435
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb3435
This article is cited by
-
Time series analysis of TP53 gene mutations in recurrent HPV-negative vulvar squamous cell carcinoma
Modern Pathology (2019)
-
The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer
Breast Cancer Research (2018)
-
Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer
Scientific Reports (2017)
